What this site is for
It exists to answer a question that advertising does not: what is this trend actually, and what does the evidence and the regulatory status support? Facial change after rapid weight loss is real and is worth understanding. The label applied to it is not a diagnosis, and a good deal of what is marketed under that label is unsupported. Separating the two is the whole purpose of this review.
What it deliberately does not do
It does not state what Chongqing West District Hospital offers in relation to GLP-1 medicines or weight-loss-related facial change, because that has not been verified, and it carries no booking prompt for any such service. It does not name a medicine by brand or by international non-proprietary name, does not name a product or device, does not quote dosages or prices, does not recommend a medicine, and does not diagnose. It does not cite individual studies, and it describes the state of the evidence in general terms.
The facts kept visible
Three facts are repeated wherever they are relevant. GLP-1 face is a popular label rather than a diagnosis. The underlying facial change — facial fat loss, and skin that does not always retract — is real and follows rapid weight loss from any cause. And the evidence base for treatments marketed specifically for it is thin: no treatment is specific to it, and none is approved for it.
How the content is reviewed and corrected
Ke He, MD, Deputy Director and Head of Skin & Laser Aesthetics, is the responsible physician. Because this subject moves quickly, the review is maintained on a three-month cycle rather than the twelve-month cycle used elsewhere in this cluster, and an out-of-cycle revision is made when a regulatory status or a labelled indication changes. If you find something unclear, out of date or wrong, the contact page explains how to tell us.